Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: Implications for pathological practice

Modern Pathology

Volumn 24, Issue 8, 2011, Pages 1128-1138

  Van Leenders, Geert J ^a   Boormans, Joost L ^b   Vissers, Cornelis J ^a   Hoogland, A Marije ^a   Bressers, Anke A ^a   Furusato, Bungo ^c   Trapman, Jan ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c International Pathology Laboratory   (Japan)

Author keywords

ERG; fusion; immunohistochemistry; prostate cancer; translocation

Indexed keywords

ANTIBODY; ANTIBODY EPR3864; MESSENGER RNA; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER INFILTRATION; CLINICAL ARTICLE; GENE FUSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE TUMOR; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANS-ACTIVATORS;

EID: 79961031183     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.65     Document Type: Article

References (45)

1. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648. (Pubitemid 41528150)
2. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009;6:429-439.
3. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8:497-511.
4. Pflueger D, Rickman DS, Sboner A, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009;11:804-811.
5. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008;68:7629-7637.
6. Esgueva R, Perner S, LaFargue CJ, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 2010;23: 539-546.
7. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008;68:73-80. (Pubitemid 351380107)
8. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66: 3396-3400.
9. Hermans KG, Bressers AA, van der Korput HA, et al. Two unique novel prostate-specific and androgenregulated fusion partners of ETV4 in prostate cancer. Cancer Res 2008;68:3094-3098.
10. Hermans KG, van der Korput HA, van Marion R, et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 2008;68:7541-7549.
11. Tomlins SA, Rhodes DR, Yu J, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008;13:519-528. (Pubitemid 351763901)
12. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26: 4596-4599. (Pubitemid 47037039)
13. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31: 882-888. (Pubitemid 47165141)
14. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-1695. (Pubitemid 350249347)
15. Nam RK, Sugar L, Wang Z, et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007;6:40-45. (Pubitemid 46294173)
16. Wang J, Cai Y, Ren C, et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006; 66:8347-8351. (Pubitemid 44449142)
17. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69:1400-1406.
18. Mosquera JM, Perner S, Demichelis F, et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol 2007;212:91-101. (Pubitemid 46746294)
19. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009;15:6398-6403.
20. Park K, Tomlins SA, Mudaliar KM, et al. Antibodybased detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010;12:590-598.
21. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
22. Albadine R, Latour M, Toubaji A, et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol 2009;22:1415-1422.
23. Fine SW, Gopalan A, Leversha MA, et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010;23:1325-1333.
24. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544. (Pubitemid 46631996)
25. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009;15:4706-4711.
26. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007;60:1238-1243. (Pubitemid 350084545)
27. Saramaki OR, Harjula AE, Martikainen PM, et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008;14:3395-3400.
28. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol 2009;22:359-365.
29. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008;21:67-75. (Pubitemid 351172158)
30. Zhang S, Pavlovitz B, Tull J, et al. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization. Diagn Mol Pathol 2010;19: 151-156.
31. Herawi M, Parwani AV, Irie J, et al. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol 2005;29:874-880. (Pubitemid 40885009)
32. Wolters T, van der Kwast TH, Vissers CJ, et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol 2010;34:35-43.
33. Wang W, Sun X, Epstein JI. Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study. Am J Surg Pathol 2008;32:851-857.
34. Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002;26:1588-1596. (Pubitemid 35387221)
35. Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 2002;26:921-925. (Pubitemid 34747645)
36. Magi-Galluzzi C, Luo J, Isaacs WB, et al. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol 2003;27:1128-1133. (Pubitemid 36909534)
37. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol 2003;27:772-778. (Pubitemid 36617513)
38. Ali TZ, Epstein JI. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Am J Surg Pathol 2008;32:1890-1895.
39. Osunkoya AO, Hansel DE, Sun X, et al. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol 2008;32: 461-467. (Pubitemid 351398939)
40. van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, et al. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001;195:563-570. (Pubitemid 34030794)
41. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008;14:3380-3385.
42. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51. (Pubitemid 46026500)
43. Clark J, Attard G, Jhavar S, et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2008;27: 1993-2003. (Pubitemid 351442741)
44. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-8341. (Pubitemid 44449140)
45. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27: 253-263.